Introduction
Malignant melanomas are aggressive tumors that usually occur on the skin. Skin melanomas have been studied extensively, and clear-cut staging, treatment, and prognostic information is available. However, melanomas occurring in the mucous membranes, which are relentlessly malignant, are very uncommon, and the available information on these tumors has come in bits from case reports and small case series.
The incidence of mucosal melanomas has remained largely stable over the years, unlike the incidence of cutaneous melanomas, which appears to be continuously increasing with the passing years. The lack of data on mucosal melanomas has made the formulation of treatment protocols difficult.
In an effort to help fill the void, we conducted a retrospective study at Tata Memorial Hospital in Mumbai, a tertiary care referral center for cancer patients in India with a substantial patient load.
Patients and methods
The purpose of this study was to determine if we could establish any pattern of occurrence, treatment response/failure, and outcomes in terms of the Asian Indian populace. We searched our hospital records to identify all cases of oral mucosal melanoma that had been at Tata Memorial Hospital from 1986 through 2007. The rarity of this condition was highlighted by the fact that we found only 13 such cases during that 22-year period.
Results
The 13 cases involved 8 men and 5 women, aged 26 to 70 years (mean: 37.5). Therefore, in this small sample at least, there was a slight preponderance of males and no predilection for any age. More than half of the tumors were located in the lower alveolus (table 1).
All of these patients had been offered surgery with curative intent. A total of 9 patients underwent neck dissection in addition to the primary excision, and 7 were administered adjuvant radiation therapy. No patient was given primary chemotherapy or immunotherapy.
Long-term follow-up data were available for 11 patients. Eight of these patients developed metastatic disease following their index treatment. Of these 8 patients, 7 developed a metastasis within 1 year (table 2). Only 1 of the 8 who developed a distant metastasis also experienced a local recurrence (table 3). The fact that mucosal melanoma has a greater tendency for distant metastasis than for local recurrence appears to explain why adjuvant radiotherapy has not shown any consistent benefit so far.
As expected, our findings with respect to survival were dismal. Despite aggressive treatment, only 3 of the 13 patients (23.1%) were alive after 2 years (table  4 ). The gloomy outlook was illustrated by the case of a 26-year-old woman who presented to the head and neck outpatient department with a 2-month history of a pigmented lesion on the upper alveolus (figure 1). Computed tomography (CT) of the head revealed localized disease (figure 2). A premaxillectomy was performed, and the histopathology report documented clear margins. Very soon after discharge, however, the patient developed nodal metastases, and she required a radical neck dissection. On both occasions, the absence of metastases elsewhere was confirmed.
Two months after her second surgery, the patient was found to have extensive lung metastases (figure 3), and she died soon thereafter. This case was not an exception, as most reports of this disease described a similar outcome despite apparently curative treatment.
Discussion
Malignant melanomas arise from melanocytes, which are protective cells that safeguard the skin against harmful ultraviolet rays. However, the function of melanocytes in the mucosa is not clearly understood.
Malignant mucosal melanomas involving the head and neck are very rare, accounting for less than 1% of all cases of melanoma. They tend to be very aggressive, and outcomes are generally very poor. Reported 5-year survival rates are 15% for all head and neck mucosal melanomas, 18% for gingival lesions, and 11% for palatal lesions. 1 Median survival is less than 2 years. 1 Affected patients tend to present at an advanced stage because the site of disease is relatively less obvious. These tumors tend to grow vertically, and most are 4.0 mm or thicker at presentation. The normal Clark classification of the level of invasion cannot be applied to mucosal melanomas, which makes establishing a prognosis even more difficult.
The rarity of these tumors has precluded any meaningful research into their cure. It has been reported that 48% of all oronasal mucosal melanomas occur in the oral cavity, 44% in the nasal cavity, and 8% in the sinuses (8%). 1 Melanomas account for 0.5% of all oral cavity malignancies. 2 About 40% of oral melanomas develop on the hard or soft palate; the next most common location is the gingiva. 1 Lesions have also been found on the buccal mucosa, lip, tongue, floor of the mouth, and uvula.
Most of the available information on this disease comes from case reports or small series. In an earlier report from India, Doval et al studied a series of 14 patients seen over 10 years; they, too, found a very dismal survival picture, with the longest survival being 30 months despite treatment. 3 Still, reports from developing countries are especially scant, which makes it difficult to formulate clear-cut guidelines for management. 4 Surgery with clear margins has always been considered to be the mainstay of treatment, 5 but the role of elective neck dissection and adjuvant radio-and chemotherapy has not been clearly defined. In vitro and in vivo data have shown large variations in the radiosensitivity of melanomas, and the optimal radiotherapy schedule for curative treatment has not been established. 5 In a report of their study of 40 cases at M.D. Anderson Cancer Center, Liebross et al recommended adjuvant radiotherapy for all patients with melanoma of the nasal or paranasal sinuses, for those with lesions larger than 4 cm, and for those with close surgical margins in the oral cavity. 6 Adjuvant radiotherapy appears to be beneficial in achieving local control. [7] [8] [9] [10] Even the published studies we do have are disadvantaged by the fact that most are retrospective. They are also handicapped by a selection bias, since radiotherapy was usually given to patients whose margins were compromised or who had other factors suggestive of a poor prognosis. In a review by Krengli et al, the authors concluded that radiotherapy has a definite role after noncurative excision and in inoperable disease, but its role after apparently curative resection is not clear. 10 The same is true for the scheduling and dosing of radiation treatments.
In a retrospective study of radiotherapy for head and neck mucosal melanoma in Australia, Bridger et al reported a 5-year survival rate of 46%, but this is exceptional. 11 Little information on long-term outcomes is available because of the poor survival rates and the paucity of documented cases. Nevertheless, some longer-term data have been published. Nandapalan et al reported 20-year survival figures in England that were, as to be expected, poor (12%). 7 In Amsterdam, Meleti et al reported 30% survival at 5 years and 0% at 10 years. 4 The diagnosis of melanin-producing lesions is easily made by finding dopa-positive melanocytes in tissue, but amelanotic lesions require immunohistochemistry. The prognosis for patients with amelanotic lesions is worse than that for patients with pigmented lesions. 7 Positivity with S-100 protein, which is relatively specific for neural tissue, has been reported in 86 to 100% of tissues. 12, 13 However, this protein is known to be present in a number of normal and neoplastic tissues, as well. 12 The utility of HMB-45 staining was suggested in two studies published 25 years apart. 12, 14 The role of microsatellite instability has not been clearly defined, although studies have appeared sporadically. 15 The role of elective neck dissection in an apparently N0 neck is far from clear. One option that has been suggested is sentinel lymph node sampling. However, this will remain experimental until we have clear evidence of its efficacy in prolonging survival. It is clear that mucosal melanomas are aggressive malignancies, but their staging, optimal treatment, and prognostic factors are far from clear, so further research is needed.
Even though our study involved only 13 patients, it still represents one of the largest series of oral mucosal melanoma patients to be reported from the Indian subcontinent.
